RenovoRx Announces Publication Of Results Of Pre-Clinical Studies Support Efficacy And Drug Delivery Mechanism Potential Of The Co's TAMP Therapy Platform To Improve Targeted Cancer Drug Treatment Delivery
Data shows that the Trans-Arterial Micro-Perfusion (TAMP) platform increases intra-arterial pressure, improving drug delivery with 100-fold increase local tissue concentration of the therapy
TAMP offers the potential to increase efficacy, improve safety and widen therapeutic window of drugs or other agents
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced a publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx's Trans-Arterial Micro-Perfusion ("TAMP") therapy platform. The data was published online in the peer-reviewed Journal of Vascular Interventional Radiology("JVIR") journal and will also be published in the print version.